

# Darren Charles Tomlinson

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/9161031/publications.pdf>

Version: 2024-02-01

77  
papers

3,576  
citations

136740

32  
h-index

143772

57  
g-index

82  
all docs

82  
docs citations

82  
times ranked

5634  
citing authors

#	ARTICLE	IF	CITATIONS
1	Purification and Analysis of Circulating Lipid Particles. <i>Methods in Molecular Biology</i> , 2022, 2419, 193-212.	0.4	1
2	Affimer Tagged Cubosomes: Targeting of Carcinoembryonic Antigen Expressing Colorectal Cancer Cells Using <i>In Vitro</i> and <i>In Vivo</i> Models. <i>ACS Applied Materials &amp; Interfaces</i> , 2022, 14, 11078-11091.	4.0	41
3	Affinity purification of fibrinogen using an Affimer column. <i>Biochimica Et Biophysica Acta - General Subjects</i> , 2022, 1866, 130115.	1.1	0
4	One-step gold nanoparticle size-shift assay using synthetic binding proteins and dynamic light scattering. <i>Sensors and Actuators B: Chemical</i> , 2022, 361, 131709.	4.0	4
5	Protein-conjugated microbubbles for the selective targeting of <i>S. aureus</i> biofilms. <i>Biofilm</i> , 2022, 4, 100074.	1.5	5
6	Rapid Quantification of <i>C. difficile</i> Glutamate Dehydrogenase and Toxin B (TcdB) with a NanoBIT Split-Luciferase Assay. <i>Analytical Chemistry</i> , 2022, 94, 8156-8163.	3.2	6
7	Affimers and nanobodies as molecular probes and their applications in imaging. <i>Journal of Cell Science</i> , 2022, 135, .	1.2	4
8	Fibrinogen interaction with complement C3: a potential therapeutic target to reduce thrombosis risk. <i>Haematologica</i> , 2021, 106, 1616-1623.	1.7	9
9	Affimer-based impedimetric biosensors for fibroblast growth factor receptor 3 (FGFR3): a novel tool for detection and surveillance of recurrent bladder cancer. <i>Sensors and Actuators B: Chemical</i> , 2021, 326, 128829.	4.0	10
10	Selective Affimers Recognise the BCL2 Family Proteins BCL2L and MCL1 through Noncanonical Structural Motifs**. <i>ChemBioChem</i> , 2021, 22, 232-240.	1.3	9
11	Selection and characterisation of Affimers specific for CEA recognition. <i>Scientific Reports</i> , 2021, 11, 744.	1.6	11
12	Reagentless Affimer- and antibody-based impedimetric biosensors for CEA-detection using a novel non-conducting polymer. <i>Biosensors and Bioelectronics</i> , 2021, 178, 113013.	5.3	28
13	RAS-inhibiting biologics identify and probe druggable pockets including an SH3 allosteric site. <i>Nature Communications</i> , 2021, 12, 4045.	5.8	19
14	Piggybacking on the Cholera Toxin: Identification of a CTB-Binding Protein as an Approach for Targeted Delivery of Proteins to Motor Neurons. <i>Bioconjugate Chemistry</i> , 2021, 32, 2205-2212.	1.8	10
15	Isolation of Artificial Binding Proteins (Affimer Reagents) for Use in Molecular and Cellular Biology. <i>Methods in Molecular Biology</i> , 2021, 2247, 105-121.	0.4	7
16	Characterization and applications of a Crimean-Congo hemorrhagic fever virus nucleoprotein-specific Affimer: Inhibitory effects in viral replication and development of colorimetric diagnostic tests. <i>PLoS Neglected Tropical Diseases</i> , 2020, 14, e0008364.	1.3	4
17	Exploiting nanobodies and Affimers for superresolution imaging in light microscopy. <i>Molecular Biology of the Cell</i> , 2019, 30, 2737-2740.	0.9	36
18	Affimer "Enzyme" Inhibitor Switch Sensor for Rapid Wash-free Assays of Multimeric Proteins. <i>ACS Sensors</i> , 2019, 4, 3014-3022.	4.0	21

#	ARTICLE	IF	CITATIONS
19	Affimers as anti-idiotypic affinity reagents for pharmacokinetic analysis of biotherapeutics. <i>BioTechniques</i> , 2019, 67, 261-269.	0.8	10
20	Affimer reagents as tools in diagnosing plant virus diseases. <i>Scientific Reports</i> , 2019, 9, 7524.	1.6	10
21	Control of conformation in $\alpha$ -helix mimicking aromatic oligoamide foldamers through interactions between adjacent side-chains. <i>Organic and Biomolecular Chemistry</i> , 2019, 17, 3861-3867.	1.5	11
22	Affimer proteins as a tool to modulate fibrinolysis, stabilize the blood clot, and reduce bleeding complications. <i>Blood</i> , 2019, 133, 1233-1244.	0.6	17
23	Sensitive and selective Affimer-functionalised interdigitated electrode-based capacitive biosensor for Her4 protein tumour biomarker detection. <i>Biosensors and Bioelectronics</i> , 2018, 108, 1-8.	5.3	57
24	Non-immunoglobulin scaffold proteins: Precision tools for studying protein-protein interactions in cancer. <i>New Biotechnology</i> , 2018, 45, 28-35.	2.4	20
25	Affimer proteins for F-actin: novel affinity reagents that label F-actin in live and fixed cells. <i>Scientific Reports</i> , 2018, 8, 6572.	1.6	38
26	Affimer proteins inhibit immune complex binding to Fc $\gamma$ RIIIa with high specificity through competitive and allosteric modes of action. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2018, 115, E72-E81.	3.3	36
27	Ortsspezifische Funktionalisierung von Affimern für die DNA-PAINT-Mikroskopie. <i>Angewandte Chemie</i> , 2018, 130, 11226-11230.	1.6	11
28	FGFR3 mutation increases bladder tumourigenesis by suppressing acute inflammation. <i>Journal of Pathology</i> , 2018, 246, 331-343.	2.1	33
29	Site-Specific Labeling of Affimers for DNA-PAINT Microscopy. <i>Angewandte Chemie - International Edition</i> , 2018, 57, 11060-11063.	7.2	71
30	Antibody Mimetics for the Detection of Small Organic Compounds Using a Quartz Crystal Microbalance. <i>Analytical Chemistry</i> , 2017, 89, 3051-3058.	3.2	20
31	Interfacing native and non-native peptides: using Affimers to recognise $\alpha$ -helix mimicking foldamers. <i>Chemical Communications</i> , 2017, 53, 2834-2837.	2.2	15
32	Ultraefficient Cap-Exchange Protocol To Compact Biofunctional Quantum Dots for Sensitive Ratiometric Biosensing and Cell Imaging. <i>ACS Applied Materials &amp; Interfaces</i> , 2017, 9, 15232-15244.	4.0	34
33	Hypofibrinolysis in diabetes: a therapeutic target for the reduction of cardiovascular risk. <i>Cardiovascular Diabetology</i> , 2017, 16, 34.	2.7	95
34	Development of an Affimer-antibody combined immunological diagnosis kit for glypican-3. <i>Scientific Reports</i> , 2017, 7, 9608.	1.6	24
35	Alternative reagents to antibodies in imaging applications. <i>Biophysical Reviews</i> , 2017, 9, 299-308.	1.5	46
36	Ubiquitination of basal VEGFR2 regulates signal transduction and endothelial function. <i>Biology Open</i> , 2017, 6, 1404-1415.	0.6	15

#	ARTICLE	IF	CITATIONS
37	Generation of specific inhibitors of SUMO-1 and SUMO-2/3 mediated protein-protein interactions using Affimer (Adhiron) technology. <i>Science Signaling</i> , 2017, 10, .	1.6	44
38	Isolation of isoform-specific binding proteins (Affimers) by phage display using negative selection. <i>Science Signaling</i> , 2017, 10, .	1.6	26
39	Upregulated WEE1 protects endothelial cells of colorectal cancer liver metastases. <i>Oncotarget</i> , 2017, 8, 42288-42299.	0.8	7
40	Affimer proteins are versatile and renewable affinity reagents. <i>ELife</i> , 2017, 6, .	2.8	151
41	VEGF-A isoforms program differential VEGFR2 signal transduction, trafficking and proteolysis. <i>Biology Open</i> , 2016, 5, 571-583.	0.6	43
42	<sc>VEGFR2</sc> Trafficking, Signaling and Proteolysis is Regulated by the Ubiquitin Isopeptidase <sc>USP8</sc>. <i>Traffic</i> , 2016, 17, 53-65.	1.3	29
43	A place for precision medicine in bladder cancer: targeting the FGFRs. <i>Future Oncology</i> , 2016, 12, 2243-2263.	1.1	39
44	Label-free electrochemical impedance biosensor to detect human interleukin-8 in serum with sub-pg/ml sensitivity. <i>Biosensors and Bioelectronics</i> , 2016, 80, 607-613.	5.3	111
45	Selective and Potent Proteomimetic Inhibitors of Intracellular Protein-Protein Interactions. <i>Angewandte Chemie</i> , 2015, 127, 3003-3008.	1.6	24
46	The cellular response to vascular endothelial growth factors requires co-ordinated signal transduction, trafficking and proteolysis. <i>Bioscience Reports</i> , 2015, 35, .	1.1	50
47	Development and characterisation of a 3D multi-cellular <i>in vitro</i> model of normal human breast: a tool for cancer initiation studies. <i>Oncotarget</i> , 2015, 6, 13731-13741.	0.8	26
48	Trivalent Gd-DOTA reagents for modification of proteins. <i>RSC Advances</i> , 2015, 5, 96194-96200.	1.7	9
49	Selective and Potent Proteomimetic Inhibitors of Intracellular Protein-Protein Interactions. <i>Angewandte Chemie - International Edition</i> , 2015, 54, 2960-2965.	7.2	82
50	An siRNA-based functional genomics screen for the identification of regulators of ciliogenesis and ciliopathy genes. <i>Nature Cell Biology</i> , 2015, 17, 1074-1087.	4.6	215
51	Exploration of the HIF-1/p300 interface using peptide and Adhiron phage display technologies. <i>Molecular BioSystems</i> , 2015, 11, 2738-2749.	2.9	35
52	Vascular endothelial growth factors: multitasking functionality in metabolism, health and disease. <i>Journal of Inherited Metabolic Disease</i> , 2015, 38, 753-763.	1.7	44
53	Inhibition of complement C3 and fibrinogen interaction: a potential novel therapeutic target to reduce cardiovascular disease in diabetes. <i>Lancet, The</i> , 2015, 385, S57.	6.3	19
54	Phage display selected magnetite interacting Adhiron for shape controlled nanoparticle synthesis. <i>Chemical Science</i> , 2015, 6, 5586-5594.	3.7	32

#	ARTICLE	IF	CITATIONS
55	Receptor tyrosine kinase structure and function in health and disease. <i>AIMS Biophysics</i> , 2015, 2, 476-502.	0.3	12
56	Vascular Endothelial Growth Factor A-Stimulated Signaling from Endosomes in Primary Endothelial Cells. <i>Methods in Enzymology</i> , 2014, 535, 265-292.	0.4	17
57	A High-Throughput Assay to Identify Modifiers of Premature Chromosome Condensation. <i>Journal of Biomolecular Screening</i> , 2014, 19, 176-183.	2.6	9
58	Adhiron: a stable and versatile peptide display scaffold for molecular recognition applications. <i>Protein Engineering, Design and Selection</i> , 2014, 27, 145-155.	1.0	136
59	High-Content, High-Throughput Screening for the Identification of Cytotoxic Compounds Based on Cell Morphology and Cell Proliferation Markers. <i>PLoS ONE</i> , 2014, 9, e88338.	1.1	51
60	Multidrug-resistant breast cancer: current perspectives. <i>Breast Cancer: Targets and Therapy</i> , 2014, 6, 1.	1.0	79
61	Proof of concept study to identify candidate biomarkers of fibrosis using high throughput peptide aptamer microarray and validate by enzyme linked immunosorbant assay. <i>Journal of Biomedical Science and Engineering</i> , 2013, 06, 32-42.	0.2	13
62	A Decade of FGF Receptor Research in Bladder Cancer: Past, Present, and Future Challenges. <i>Advances in Urology</i> , 2012, 2012, 1-10.	0.6	101
63	Mechanisms of FGFR3 actions in endocrine resistant breast cancer. <i>International Journal of Cancer</i> , 2012, 130, 2857-2866.	2.3	69
64	FGFR1-Induced Epithelial to Mesenchymal Transition through MAPK/PLC $\beta$ /COX-2-Mediated Mechanisms. <i>PLoS ONE</i> , 2012, 7, e38972.	1.1	82
65	Small molecule FGF receptor inhibitors block FGFR-dependent urothelial carcinoma growth in vitro and in vivo. <i>British Journal of Cancer</i> , 2011, 104, 75-82.	2.9	157
66	Structure-function studies of an engineered scaffold protein derived from Stefin A. II: Development and applications of the SQT variant. <i>Protein Engineering, Design and Selection</i> , 2011, 24, 751-763.	1.0	43
67	FGFR3 mutation affects cell growth, apoptosis and attachment in keratinocytes. <i>Experimental Cell Research</i> , 2010, 316, 2008-2016.	1.2	24
68	Altered Splicing of FGFR1 Is Associated with High Tumor Grade and Stage and Leads to Increased Sensitivity to FGF1 in Bladder Cancer. <i>American Journal of Pathology</i> , 2010, 177, 2379-2386.	1.9	57
69	Fibroblast Growth Factor Receptor 1 Promotes Proliferation and Survival via Activation of the Mitogen-Activated Protein Kinase Pathway in Bladder Cancer. <i>Cancer Research</i> , 2009, 69, 4613-4620.	0.4	111
70	Mutant fibroblast growth factor receptor 3 induces intracellular signaling and cellular transformation in a cell type- and mutation-specific manner. <i>Oncogene</i> , 2009, 28, 4306-4316.	2.6	94
71	Inactivation of the Rb pathway and overexpression of both isoforms of E2F3 are obligate events in bladder tumours with 6p22 amplification. <i>Oncogene</i> , 2008, 27, 2716-2727.	2.6	73
72	Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer. <i>Oncogene</i> , 2007, 26, 5889-5899.	2.6	112

#	ARTICLE	IF	CITATIONS
73	FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma. <i>Oncogene</i> , 2005, 24, 5218-5225.	2.6	295
74	Alternative Splicing of Fibroblast Growth Factor Receptor 3 Produces a Secreted Isoform That Inhibits Fibroblast Growth Factor-Induced Proliferation and Is Repressed in Urothelial Carcinoma Cell Lines. <i>Cancer Research</i> , 2005, 65, 10441-10449.	0.4	64
75	Regulation of Fgf10 Gene Expression in the Prostate: Identification of Transforming Growth Factor- $\beta$ 1 and Promoter Elements. <i>Endocrinology</i> , 2004, 145, 1988-1995.	1.4	31
76	Differential Effects of Transforming Growth Factor- $\beta$ 1 on Cellular Proliferation in the Developing Prostate. <i>Endocrinology</i> , 2004, 145, 4292-4300.	1.4	31
77	Sonic hedgehog regulates prostatic growth and epithelial differentiation. <i>Developmental Biology</i> , 2003, 264, 352-362.	0.9	139